KDMN News and Press, Kadmon Holdings Inc. From 05/21/20

Shares of Kadmon Holdings (NYSE: KDMN) are getting a boost on Thursday after the biopharmaceutical company reported positive results from a clinical trial for one of its most promising pipeline candidates, KD025. Kadmon Holdings' stock is up by 8.4% as of 1:05 p.m. today. KD025 is being inv...

Kadmon Holdings (NYSE: KDMN ) announces topline results from the primary analysis of a pivotal Phase 2 clinical trial, ROCKstar , evaluating lead drug belumosudil (KD025) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic...

ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, Respectively Kadmon Participating in FDA's Real-Time Oncology Review Pilot Program Conference Call Today at 8:30 a.m. Eastern Time NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Kadmon Holdings, Inc. (NYSE:KD...

NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2020. "We made encouraging progress this past quarter, having completed our pre-NDA meeting with the FDA. Base...

Janssen Signs Collaboration with ImmunoPrecise Antibodies Johnson & Johnson ( JNJ ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. ( IPATF ). The new deal offers Janssen an exclusive access to an array of novel...

Based on final minutes from its recent meeting with the FDA, Kadmon Holdings ( KDMN +3.8% ) believes that its proposed data package will be sufficient to support a marketing application seeking approval to use KD025 to treat chronic graft-versus-host-disease (GVHD). It expects to complet...

- Kadmon on Track for NDA Submission for KD025 in Q4 2020 - - Company to Announce Top-line Results from Primary Analysis in Q2 2020 - NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has received the final meeting minutes from t...

Today, we will see why Kadmon Holdings ( KDMN ) is an attractive pick in March 2020. Company overview Founded in 2009, Kadmon Holdings went public in 2016. The company is a late-stage biopharmaceutical company focused on the development and commercialization of small molecule therapies a...

NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Drug Administration (FDA) for KD025 for the treatment of patients with chronic graft-versus-hos...

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc. (NYSE:KD...